ABSTRACT
HISTORY OF IVM In vitro maturation (IVM) is not a new technology. Its use was rst reported by Pincus and Enzmann (1) in mammals in 1935. Preclinical studies were continued in animals by Edwards (2), and Edwards et al. (3) reported clinical application in humans, obtaining immature oocytes from cases with ovarian stimulation. Veeck et al. (4) achieved the rst successful birth from immature oocytes produced during an in vitro fertilization (IVF) program. ereaer, Cha et al. (5) initiated the use of immature oocytes from unstimulated ovaries of patients in a donation program. Following this, Trounson et al. (6) achieved another breakthrough in the development of IVM. ey chose immature oocytes aspirated from patients with polycystic ovary syndrome (PCOS) as a source for the procedure. Gonadotropins, estradiol, and fetal calf serum were supplemented in the medium and a 65% maturation rate was achieved within 43-47 hours of culture. en, the maturation rate was acceptable, but the pregnancy success rate was only 11.1%. However, IVM has become a mainstream choice for PCOS treatment. Patients with PCOS are hypersensitive to stimulating drugs, and ovarian stimulation for conventional IVF in PCOS patients carries the risk of severe ovarian hyperstimulation syndrome (OHSS), causing some patients to quit treatment. Use of IVM is the only method that can completely prevent OHSS.
